MEDNAX (NYSE:MD) has been assigned a $58.00 target price by research analysts at Jefferies Group in a report issued on Thursday, March 15th. The firm presently has a “hold” rating on the stock. Jefferies Group’s price target suggests a potential upside of 6.09% from the stock’s current price.
A number of other research firms have also commented on MD. BMO Capital Markets lifted their target price on shares of MEDNAX from $46.00 to $58.00 and gave the stock a “market perform” rating in a report on Monday, February 12th. Piper Jaffray assumed coverage on shares of MEDNAX in a report on Wednesday, December 13th. They issued an “overweight” rating and a $58.00 price target for the company. SunTrust Banks set a $55.00 target price on shares of MEDNAX and gave the stock a “hold” rating in a research note on Thursday, December 21st. Mizuho reaffirmed a “neutral” rating and issued a $53.00 target price (up from $49.00) on shares of MEDNAX in a research note on Friday, February 9th. Finally, Robert W. Baird upped their target price on shares of MEDNAX from $48.00 to $54.00 and gave the stock a “neutral” rating in a research note on Friday, February 9th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $55.69.
NYSE:MD opened at $54.67 on Thursday. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.18 and a quick ratio of 1.18. MEDNAX has a 1 year low of $40.56 and a 1 year high of $68.55. The company has a market capitalization of $5,236.60, a PE ratio of 17.36, a PEG ratio of 1.39 and a beta of 0.23.
MEDNAX (NYSE:MD) last posted its quarterly earnings data on Thursday, February 8th. The company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.04. MEDNAX had a net margin of 9.26% and a return on equity of 10.10%. The firm had revenue of $910.82 million during the quarter, compared to analysts’ expectations of $884.55 million. During the same quarter in the previous year, the company posted $1.00 EPS. MEDNAX’s revenue was up 9.6% on a year-over-year basis. sell-side analysts anticipate that MEDNAX will post 4.02 EPS for the current year.
In other MEDNAX news, insider John C. Pepia sold 3,000 shares of the stock in a transaction that occurred on Tuesday, March 13th. The shares were sold at an average price of $58.35, for a total transaction of $175,050.00. Following the transaction, the insider now owns 39,716 shares in the company, valued at approximately $2,317,428.60. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 2.40% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. HealthCor Management L.P. bought a new position in MEDNAX in the 4th quarter valued at approximately $67,421,000. Pzena Investment Management LLC bought a new position in MEDNAX in the 4th quarter valued at approximately $51,411,000. Earnest Partners LLC lifted its stake in MEDNAX by 48.1% in the 4th quarter. Earnest Partners LLC now owns 2,212,691 shares of the company’s stock valued at $118,246,000 after purchasing an additional 718,317 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in MEDNAX by 987.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 756,215 shares of the company’s stock valued at $32,607,000 after purchasing an additional 686,678 shares during the last quarter. Finally, Elkfork Partners LLC bought a new position in shares of MEDNAX during the fourth quarter valued at $35,423,000. Institutional investors and hedge funds own 98.53% of the company’s stock.
TRADEMARK VIOLATION WARNING: “MEDNAX (NYSE:MD) Given a $58.00 Price Target at Jefferies Group” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/08/mednax-md-given-a-58-00-price-target-by-jefferies-group-analysts.html.
MEDNAX Company Profile
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.